Identification of AKT3-HIF1å pathway as a new therapeutic target for renal cell carcinoma

2016 Fiscal Year Final Research Report

• Project/Area Number: 25462495
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Yokohama City University
• Principal Investigator: KONDO Keiichi 横浜市立大学, 附属病院, 准教授 (80363836)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: AKT / HIFα / 腎細胞癌

Outline of Final Research Achievements

We started this study from suppression experiment with renal carcinoma cell line plus siRNA for suppression of hypoxia inducible factor alpha subunit, to expression analysis of each subtype of AKT and HIF alpha subunit in surgical specimens of renal cell carcinomas and statistical analysis of relationship between expression level of these subtypes and pathological factors & prognosis.
Suppression of each AKT subtype show suppression of HIF alpha subtype, but combination of AKT subtype suppression and HIF alpha subtype suppression were different among renal carcinoma cell lines. Original histopathological factors of renal carcinoma cell line and status of von Hippel-Lindau tumor suppressor gene influenced these differences.
Expression of AKT subtype couldn't show relationship with the prognosis of renal cell carcinoma patients.

Free Research Field

泌尿器科腫瘍学